You are here

Article Text

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-1357-ESGO Factors associated with an increased risk of recurrence in endometrial cancer patients: a retrospective cohort study
Free
  1. Natalia Teixeira1,
  2. Alba Farres1,
  3. Pia Espanol2,
  4. Eva Magret1,
  5. Rocio Luna1,
  6. Cristina Soler1,
  7. Pau Martin-Malpartida3,4,
  8. Maria Jesús Macías3,4,
  9. Maria Virtudes Céspedes5 and
  10. Ramon Rovira1
  1. 1Gynecology and Obstetrics; Grup d’Oncologia Ginecològica, Institut d’Investigacions Biomédiques, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  2. 2Gynecology and Obstetrics, Hospital Universitari Son Espases, Palma de Mallorca, Spain
  3. 3Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain
  4. 4Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
  5. 5Grup d’Oncologia Ginecològica i Peritoneal, Institut d’Investigacions Biomédiques, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Abstract

Introduction/Background The aim of this study was to identify clinical and pathologic factors associated with the risk of recurrence in patients with endometrial cancer (EC).

Methodology We included patients who underwent surgery for EC in our institution between 2007 and 2019. Data on demographic characteristics, surgery and pathology reports, adjuvant treatment and follow-up was collected from electronic patient files. Patients were divided into two groups: recurrence and no recurrence. Clinical and pathologic factors were compared using Student T-test, Chi-square or Fisher’s exact test. Univariate and multivariate Cox-proportional hazard models were used to assess the impact of the evaluated factors on the risk of recurrence.

Results In total 286 patients were included in the analysis. In a mean follow-up time of 59 months, EC recurrence was diagnosed in 60 (20.9%) patients, 75% of which were diagnosed in the first 24 months after surgery. Compared to patients with no recurrence, patients with recurrent EC had more frequently type II (56.7%vs.25.2%), high-grade (61.7%vs.32.7%), stage III-IV tumors (35%vs.17.3%), tumor>2 cm (95%vs.78.8%), myometrial infiltration>50% (48.3%vs.29.2%) and lympho-vascular space invasion (LVSI; 60.9%vs.25.8%). Lymphadenectomy had been indicated more often in patients with recurrent EC (71.7%vs.44.2%), however, there was no association between performance of lymphadenectomy and EC recurrence. In univariate survival analysis, risk of recurrence was higher in patients with type II (HR:4.12;p<0.001), high-grade tumors (HR:3.06;p<0.001), tumor>2 cm (HR:4.93;p=0.007), myometrial infiltration>50% (HR:2.43;p=0.001), cervix infiltration (HR:2.29;p<0.001), adnexal tumor (HR:1.97;p=0.031), LVSI (HR:4.39,p=0.001) and stage IV (HR:6.85;p<0.001). In multivariate analysis, only LVSI remained significantly associated with an increased risk of recurrence (HR:5.36;p=0.017).

Conclusion LVSI is an independent risk factor for EC recurrence, while performing lymphadenectomy had no impact on the risk of recurrence. Identifying patients with a higher risk of EC recurrence is important in order to concentrate follow-up efforts on patients who can benefit the most from it.

https://doi.org/10.1136/ijgc-2022-ESGO.313

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.